SSO2 Therapy


SSO2 Therapy Reduces Infarct Size by 26%1

TherOx has developed a proprietary medical technology called SuperSaturated Oxygen (SSO2) Therapy. SSO2 Therapy creates a highly oxygenated saline solution and combines it with the patient’s arterial blood to provide focal hyperbaric oxygen therapy to ischemic (oxygen-deprived) tissue. The focus of SSO2 Therapy is for the treatment of acute myocardial infarction (heart attack).

Current standard of care for heart attack patients involves mechanically opening the blocked artery using percutaneous coronary intervention (PCI), otherwise known as angioplasty and stenting. The widespread adoption of PCI has reduced early mortality post-heart attack, but significant scarring (infarction) is often present in the most severe ST-elevation myocardial infarction (STEMI) patients. Significant myocardial tissue (heart muscle) death and sizable scarring may be present even after the left anterior descending (LAD) artery has been stented. This myocardial damage is linked to increased risk of heart failure and long-term mortality.2

SSO2 Therapy is a novel treatment that complements PCI and is designed to minimize myocardial damage caused by acute myocardial infarction in qualifying patients suffering a LAD STEMI event who are treated with primary PCI within 6 hours of symptom onset. SSO2 Therapy delivers superoxygenated arterial blood directly to at-risk myocardial tissue and is performed in the cardiac catheterization laboratory immediately after PCI is completed.

1Stone, et al. Circ Cardiovasc Interv. 2009 Oct; 2:366-375. Subset data on file at TherOx, Inc.
2Stone GW, et al. Relationship between infarct size and outcomes following primary PCI. JACC 2016;67(14):1674-83

Caution: Federal (United States) law restricts this device to sale by or on the order of a physician. The TherOx SSO2 System is indicated for the preparation and delivery of SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient’s left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior acute myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.

Indications For Use: The TherOx DownStream System is indicated for the preparation and delivery of SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient’s left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior acute myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.

overview Thumbnail Row Title